| Designations: | NCI-H929 [H929] |
|
|
| Depositors: | National Cancer Institute |
|
|
| Isotype: | IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.) |
|
|
| Biosafety Level: | 1 |
|
|
| Shipped: | frozen |
|
|
| Medium & Serum: | See Propagation |
|
|
| Growth Properties: | suspension |
|
|
| Organism: | Homo sapiens (human) |
|
|
| Morphology: | lymphoblast
 |
|
|
| Source: | Organ: bone marrow
Disease: plasmacytoma; myeloma
Cell Type: B lymphocyte; |
|
|
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| NCI-H929細胞， 人骨髓瘤細胞株 |
|
|
| Receptors: | transferrin |
|
|
| Antigen Expression: | PCA-1; CD38 + |
|
|
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 9,13 D5S818: 11,12 D7S820: 10,12 THO1: 9.3 TPOX: 8,11 vWA: 14,15 |
|
|
| Cytogenetic Analysis: | Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality. |
|
|
| Age: | 62 years |
|
|
| Gender: | female |
|
|
| Ethnicity: | Caucasian |
|
|
| Comments: | This cell line was established from a malignant effusion in a patient with myeloma. The cells are positive for plasma cell antigen 1 (PCA-1), transferrin receptor, CD38 (T10), but are negative for HLA DR, CALLA and markers of early B cell development. They are negative for Epstein-Barr virus nuclear antigen (EBNA). The cells have a rearrangement of the c-myc proto oncogene and express c-myc RNA. There is also an activated ras allele. |
|
|
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C |
|
|
| Subculturing: | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 10(5) viable cells/ml.
Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: 2 to 3 times per week |
|
|
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
|
|
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
|
|
| References: | 22372: Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed:3275865
23349: Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157
23351: Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435 |
